<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Zoology</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3997DCD6-FCDF-4DF2-95E6-D84157B7B4F3"><gtr:id>3997DCD6-FCDF-4DF2-95E6-D84157B7B4F3</gtr:id><gtr:name>Rainbow Seed fund</gtr:name><gtr:address><gtr:line1>Rainbow Seed fund</gtr:line1><gtr:line2>5 Rupert Road</gtr:line2><gtr:line4>Guildford</gtr:line4><gtr:line5>Surrey</gtr:line5><gtr:postCode>GU2 7NE</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E23E4301-27EA-4E97-B6A7-41F8BD71B648"><gtr:id>E23E4301-27EA-4E97-B6A7-41F8BD71B648</gtr:id><gtr:firstName>Adrian</gtr:firstName><gtr:surname>Smith</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FJ010855%2F1"><gtr:id>6B044E30-730D-4C91-840C-398C32CD25EB</gtr:id><gtr:title>Identification of protective Chalmydia antigens using a novel technology</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/J010855/1</gtr:grantReference><gtr:abstractText>BBSRC funded research led to the discovery of a unique approach to identify antigens that confer protective immunity. This approach, known as Protecta Antigen Finding (PAF) allows discrimination of pathogen-derived antigens that mediate protection from the larger cohort that simply stimulate a response. PAF has stimulated significant interest within the vaccine industry, Seed Fund and Venture Capital sectors. To realise the commercial potential of PAF we have demonstrated PAF utility in vaginal Chlamydia infection. The key objective of this FOF application is to perform the next phase of PAF and identify the antigens that afford protection. A panel of new protective antigens against Chlamydia will provide a foundation for commercial exploitation via spin-out and/or licensing routes. The PAF project has a solid IP platform and has attracted a small amount of seed funding and developed a robust commercial and technical plan necessary to succeed in this competitive and high impact arena.</gtr:abstractText><gtr:fund><gtr:end>2014-02-28</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2012-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>156608</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Oxford Martin School</gtr:department><gtr:description>Oxford Martin School</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>825EADA0-2DB7-4316-AD4F-E4F8F6078476</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The data collected during the project has supported the maintenance of a patent on the process of identification of antigens using the Protecta Antigen Finding platform.
We have also developed further funding to support progress in this area.</gtr:description><gtr:firstYearOfImpact>2013</gtr:firstYearOfImpact><gtr:id>B74DEC6F-E34F-43E9-9F9A-8C26425AE89E</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:sector>Other</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>The work in this grant has identified that we can use a process called Protecta Antigen Finding (PAF) to help identify antigens for use in vaccines. We have performed an analysis of the repertoire of B cells and T cells that associate with protection against vaginal infection with Chlamydia trachomatis in this system. Probably the most important aspect is that the PAF process is generally applicable to antigen identification in a wide range of infectious diseases that are proving challenging in terms of protective antigen identification.</gtr:description><gtr:exploitationPathways>We are continuing to work on the use of PAF as an antigen discovery system and are in discussion with other researchers to develop further funding opportunities to support this system. We succeeded in obtaining some funding from a fund within the University of Oxford and are continuing with our efforts towards antigen identification in the Chlamydia system.
We also continue to maintain the patent and are continuing in our search for commercial partners.</gtr:exploitationPathways><gtr:id>7778196B-052E-463D-B469-587136243C69</gtr:id><gtr:sectors><gtr:sector>Agriculture, Food and Drink,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The Protecta Antigen Finding methodology is the subject of a patent held at the University of Oxford. This method has the ability to identify protective antigens (from those that are simply responded to). This is a major issue in the vaccine industry.</gtr:description><gtr:id>26A9F7EE-7A5A-46A8-84BF-A217B519D10F</gtr:id><gtr:impact>Continuation of patent. On-going discussions with companies and collaborators interested in antigen discovery and vaccine development.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>PAF</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have developed systems for measuring the immune repertoire in chickens and use or are developing similar methodologies for use in a wide range of other species.</gtr:description><gtr:id>8FBE51EA-130F-4126-8806-14431E44A434</gtr:id><gtr:impact>A range of studies are underway.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Immune repertoire analyses (avian)</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have developed systems for measuring the immune repertoire in chickens, mice and humans, we are developing similar methodologies for use in a wide range of other species.</gtr:description><gtr:id>667BC46D-B46B-4648-A3EB-8F21A270C37D</gtr:id><gtr:impact>Collaborations underway.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>immune repertoire analyses (general)</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">BB/J010855/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>